Premium
Comparing Effects of Native and Nanoencapsualted Epigallocatechin Gallate on Liver Fat Content in LDL Receptor Null Mice
Author(s) -
Li Chuan,
Zhang Jia,
Nie Shufang,
Cao Jun,
Wang Shu
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.lb373
Subject(s) - epigallocatechin gallate , chemistry , triglyceride , ldl receptor , endocrinology , medicine , nanocarriers , antioxidant , pharmacology , biochemistry , lipoprotein , cholesterol , polyphenol , drug delivery , organic chemistry
Objectives We successfully synthesize epigallocatechin gallate (EGCG) nanocarriers (E‐nano), which have anti‐atherogenic and anti‐inflammatory bioactivities. But their effects on liver fat, primarily triglyceride, content have not been known yet. Therefore, we compared the effects of native EGCG and different types of E‐nano on liver fat content in LDL receptor null (LDLr‐/‐) mice. Methods Mice were fed an atherogenic diet and received weekly intravenous injection of the following 6 treatments for 20 weeks: saline, high dose (25 mg/kg body weight) of EGCG (EGCG‐H), E‐nano (E‐nano‐H), macrophage‐targeting E‐nano (TE‐nano‐H), and low dose (10 mg/kg body weight) of E‐nano (E‐nano‐L), macrophage‐targeting E‐nano (TE‐nano‐L). Liver lipids were extracted by a chloroform/methanol mixture. Liver triglyceride content was measured using an enzymatic method. Liver fat content was determined using an EchoMRI scanning method. Results Compared to other treatments, native EGCG significantly decreased liver fat content in LDLr‐/‐ mice. Both the enzymatic method and EchoMRI scanning demonstrated the similar results.Conclusions Native EGCG, not nanoencapsulated EGCG, decreased liver fat content in LDLr‐/‐ mice fed an atherogenic diet. Grant Funding Source: NIH 1R15AT007013‐01, Scholarship of Nanchang University.